Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Taiwan ETF (EWT) vs Invesco Ltd. (IVZ) Price & Performance

iShares MSCI Taiwan ETFTrade
Invesco Ltd.Trade

Price performance (Past 24H)

Key statistics

iShares MSCI Taiwan ETF vs Invesco Ltd. — how do they compare? iShares MSCI Taiwan ETF trades at $114.31 (market cap $12.74B), while Invesco Ltd. trades at $29.51 (market cap $13.28B). The key difference: iShares MSCI Taiwan ETF and Invesco Ltd. are close in size by market cap, and Invesco Ltd. pays a 2.86% dividend while iShares MSCI Taiwan ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 52 Days and Invesco Ltd. for 77 Days on average.

EWTIVZ
Market Cap
$12.74B$13.28B
Volume
8,470,9203,698,033
Sector
Broad Market / FactorFinancials
52-Week High
$118.00$33.31
52-Week Low
$60.03$22.44
Typical Hold Time
52 Days77 Days
Enterprise Value
—$23.45B
Dividend Yield
—2.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Taiwan ETF

EWT (iShares MSCI Taiwan ETF) trades at $113.34, down 2.49% on the day, with a bullish technical signal from moving averages despite neutral oscillators. The ETF remains heavily concentrated in Taiwan's semiconductor sector, particularly TSMC, benefiting from strong AI-driven demand. Recent news highlights Taiwan's $20 billion investment in US AI infrastructure and continued institutional interest, though geopolitical tensions with China present ongoing risks.

The outlook for EWT is positive due to Taiwan's critical role in AI semiconductor supply chains and reasonable tech valuations. Key opportunities include sustained AI demand and corporate investments, while risks center on China-Taiwan geopolitical friction and semiconductor cycle volatility. Wall Street maintains a bullish stance given growth-adjusted valuation metrics.

Invesco Ltd.

IVZ trades at $30.09, down 1.34% on the day, with a bearish technical signal from moving averages and oscillators. The company reported a net loss of $281.70 million in 2025 despite revenue growth to $6.38 billion, though recent earnings beats in Q4 2025 and Q2 2026 show some operational resilience. Analyst consensus is mixed with a $33.14 price target, and the firm continues expanding its ETF suite, including the recent launch of the Invesco Nasdaq International Innovators 100 ETF.

The outlook remains cautious due to negative profitability margins and bearish technicals, but the absence of sell ratings and a dividend payment provide some support. Key risks include sustained negative net income and competitive pressures in the asset management sector, while potential upside hinges on improved earnings and AUM growth momentum.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EWT
100% Buy0% Sell
Avg holding period · 52 Days
IVZ

No sentiment data available yet.

Top news

Latest headlines on both assets

About iShares MSCI Taiwan ETF

EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.

Read more on EWT →

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ →